

From 1<sup>st</sup> Nov 2024, NT-proBNP testing will be Medicare rebatable when ordered by GPs. These biomarkers have been used primarily by cardiologists and emergency clinicians but **now GPs can request the test** to assess patients for heart failure and the test will attract a Medicare rebate.

# NT-proBNP and BNP: important for diagnosis

As Australia's population ages, congestive heart failure (CHF) is becoming an increasingly prevalent condition, particularly among elderly patients, with an estimated 1.5-2% of the population affected. The diagnosis of mild or early CHF has traditionally been difficult due to non-specific symptoms that often overlap with other conditions.

NT-proBNP testing offers a more accessible alternative to chest X-rays and echocardiograms.

NT-proBNP and BNP tests are treated as equivalent by Medicare and our laboratories.

# **Testing Frequency**

BNP or NT-proBNP will attract a Medicare benefit only once per 12-month period.

#### How it works:

NT-proBNP is released by the heart in response to increased wall stress due to volume overload, a hallmark of heart failure. Very elevated levels of these markers strongly suggest the presence of heart failure, whereas low levels rule out CHF as a cause of the patient's symptoms.

# **Healius Pathology network:**



# **NT-proBNP Testing for Heart Failure Diagnosis**

### Likelihood of heart failure:



<sup>\*</sup>Interpretative reference cut-points are provided according to age.

## Request NT-proBNP for patients presenting with:

- Dyspnea: Acute or chronic shortness of breath, especially where heart failure is suspected but not confirmed.
- **Oedema:** Peripheral oedema, unexplained fatigue, or elevated JVP.
- Comorbidity: A history of lung disease where you are assessing for coexisting heart failure.
- **Risk Factors:** Patients who are at risk of CHF due to age, hypertension, or diabetes but do not yet show clear signs of the condition.

## Request NT-proBNP to:

Assess whether a patient presenting with one of the above factors is requiring echocardiography.

## Benefits over traditional diagnostic methods:



**Accessible:** Easier to access compared to echocardiography, especially in non-urban settings.



**Time-sensitive:** Faster results compared to waiting for imaging.



**Specificity:** High negative predictive value – a low NT-proBNP level virtually excludes CHF, allowing you to focus on alternative diagnoses.

To order, simply request a BNP panel test.



Abbott Pathology | Dorevitch Pathology Laverty Pathology | QML Pathology | TML Pathology Western Diagnostic Pathology

